• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Harris Matthew Scott gifted 67,787 shares (SEC Form 4)

    3/11/25 4:05:11 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Harris Matthew Scott

    (Last) (First) (Middle)
    C/O ALTIMMUNE, INC.
    910 CLOPPER ROAD, SUITE 201S

    (Street)
    GAITHERSBURG MD 20878

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Altimmune, Inc. [ ALT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.0001 03/07/2025 G 67,787 D $0 14,069 D(1)
    Common Stock, par value $0.0001 67,787 I(1) By Matthew Scott Harris Trust
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On March 7, 2025, the reporting person transferred 67,787 shares of common stock to the Matthew Scott Harris Trust for no consideration. The reporting person is trustee of the trust, and the reporting person and members of his immediate family are the sole beneficiaries of the trust. The reporting person remains the beneficial owner of the securities held by the trust.
    /s/ Greg Weaver, as Attorney-in Fact 03/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    12/1/2022$20.00Buy
    Goldman
    12/29/2021$30.00Buy
    Jefferies
    More analyst ratings

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

      GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data

      5/19/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Participate at Two Upcoming Investor Conferences

      GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)Tuesday, May 20, 2025Fireside Chat at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 4, 2025Fireside Chat at 9:55 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section

      5/14/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

      GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company's pemvidutide development plans and financing needs. Access to this additional capital strengthens Altimmune's ba

      5/13/25 7:00:00 AM ET
      $ALT
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance

    $ALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

      Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled

      2/25/25 7:30:00 AM ET
      $ALT
      $DXCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

      GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun

      3/27/23 4:05:00 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Appoints Raymond Jordt as Chief Business Officer

      GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option

      1/4/23 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Altimmune

      William Blair initiated coverage of Altimmune with a rating of Mkt Perform

      2/28/25 7:17:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Altimmune with a new price target

      Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

      1/8/25 7:32:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Altimmune with a new price target

      UBS initiated coverage of Altimmune with a rating of Buy and set a new price target of $26.00

      11/12/24 7:30:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      11/14/24 11:58:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/17/24 11:16:51 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/16/24 4:21:16 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/18/25 4:15:22 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/14/25 7:27:34 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Harris Matthew Scott gifted 67,787 shares (SEC Form 4)

      4 - Altimmune, Inc. (0001326190) (Issuer)

      3/11/25 4:05:11 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

      SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)

      5/15/25 11:05:50 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Altimmune Inc.

      10-Q - Altimmune, Inc. (0001326190) (Filer)

      5/13/25 4:55:02 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Altimmune, Inc. (0001326190) (Filer)

      5/13/25 7:04:35 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    Financials

    Live finance-specific insights

    See more
    • Altimmune Announces First Quarter 2025 Financial Results and Business Update

      Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceuti

      5/13/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations

      5/6/25 7:30:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Feb.

      2/27/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care